Drug-induced liver injury related to Triumeq (abacavir/lamivudine/dolutegravir) 
has not been reported in clinical trials. We report a case of hepatotoxicity 
related to Triumeq exposure in a human immunodeficiency virus-infected patient. 
Clinicians should remain aware of the risk for acute and late-onset hepatitis 
with these agents. Close monitoring is recommended.